首页> 美国卫生研究院文献>other >Evaluation of replication immunogenicity and protective efficacy of a live attenuated cold-adapted pandemic H1N1 influenza virus vaccine in non-human primates
【2h】

Evaluation of replication immunogenicity and protective efficacy of a live attenuated cold-adapted pandemic H1N1 influenza virus vaccine in non-human primates

机译:在非人最新产物中的现场病变冷适应大流行性H1N1流感病毒疫苗的复制免疫原性和保护效果评价

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

We studied the replication of influenza A/California/07/09 (H1N1) wild type (CA09wt) virus in two non-human primate species and used one of these models to evaluate the immunogenicity and protective efficacy of a live attenuated cold-adapted vaccine, which contains the hemagglutinin and neuraminidase from the H1N1 wild type virus and six internal protein gene segments of the A/Ann Arbor/6/60 cold-adapted (ca) master donor virus. We infected African green monkeys (AGMs) and rhesus macaques with 2 × 106 TCID50 of CA09wt and CA09ca influenza viruses. The virus replicated in the upper respiratory tract of all animals but the titers in upper respiratory tract tissues of rhesus macaques were significant higher than in AGMs (mean peak titers 104.5 TCID50/g and 102.0 TCID50/g on days 4 and 2 post-infection, respectively; p<0.01). Virus replication was observed in the lungs of all rhesus macaques (102.0–105.4TCID50/g) whereas only 2 out of 4 AGMs had virus recovered from the lungs (102.5– 103.5 TCID50/g). The CA09ca vaccine virus was attenuated and highly restricted in replication in both AGMs and rhesus macaques. We evaluated the immunogenicity and protective efficacy of the CA09ca vaccine in rhesus macaques because CA09wt virus replicated more efficiently in this species. One or two doses of vaccine were administered intranasally and intratracheally to rhesus macaques. For the two-dose group, the vaccine was administered 4-weeks apart. Immunogenicity was assessed by measuring hemagglutination-inhibiting (HAI) antibodies in the serum and specific IgA antibodies to CA09wt virus in the nasal wash. One or two doses of the vaccine elicited a significant rise in HAI titers (range 40–320). Two doses of CA09ca elicited higher pH1N1-specific IgA titers than in the mock-immunized group (p<0.01). Vaccine efficacy was assessed by comparing titers of CA09wt challenge virus in the respiratory tract of mock immunized and CA09ca vaccinated monkeys. Significantly lower virus titers were observed in the lungs of vaccinated animals than mock-immunized animals (p ≤ 0.01). Our results demonstrate that AGMs and rhesus macaques support the replication of pandemic H1N1 influenza virus to different degrees and a cold-adapted pH1N1 vaccine elicits protective immunity against pH1N1 virus infection in rhesus macaques.
机译:我们研究了两种非人类灵长类动物中甲型/加利福尼亚/ 07/09(H1N1)流感野生型(CA09wt)病毒的复制,并使用其中一种模型评估了减毒活的减毒活疫苗的免疫原性和保护功效,其中包含来自H1N1野生型病毒的血凝素和神经氨酸酶,以及A / Ann Arbor / 6/60冷适应的(ca)主供体病毒的六个内部蛋白质基因片段。我们用2×10 6 TCID50的CA09wt和CA09ca流感病毒感染了非洲绿猴(AGMs)和恒河猴。该病毒可在所有动物的上呼吸道中复制,但猕猴的上呼吸道组织中的滴度明显高于AGM(平均峰值滴度TCID50 / g为10 4.5 和10 2.0)。 感染后第4天和第2天的TCID50 / g; p <0.01)。在所有恒河猕猴的肺中均观察到病毒复制(10 2.0 –10 5.4 TCID50 / g),而只有四分之二的AGM从肺中恢复了病毒(10 2.5 – 10 3.5 TCID50 / g)。 CA09ca疫苗病毒在AGM和猕猴中的复制均受到减毒并受到高度限制。我们评估了CA09ca疫苗在恒河猴中的免疫原性和保护效果,因为CA09wt病毒在该物种中的复制效率更高。鼻内和气管内给予恒河猴猕猴一或两剂疫苗。对于两剂组,疫苗间隔4周施用。通过测量血清中的血凝抑制(HAI)抗体和鼻洗液中针对CA09wt病毒的特异性IgA抗体来评估免疫原性。一或两剂疫苗引起HAI滴度显着升高(范围40-320)。与模拟免疫组相比,两剂CA09ca引起更高的pH1N1特异性IgA滴度(p <0.01)。通过比较模拟接种的和接种CA09ca的猴子的呼吸道中CA09wt攻击病毒的滴度来评估疫苗效力。在疫苗接种的动物的肺部观察到的病毒滴度明显低于模拟免疫的动物(p≤0.01)。我们的结果表明,AGM和恒河猕猴在不同程度上支持大流行性H1N1流感病毒的复制,冷适应的pH1N1疫苗引发针对恒河猴的pH1N1病毒感染的保护性免疫。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号